Gin-Ho Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gin-Ho Lo has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
- Kwok-Hung Lai
Department of Internal Medicine, Kaohsiung Veterans General Hospital, School of Medicine, National Yang Ming University, Taiwan, ROC
21 shared publications J S Cheng
11 shared publications- Ping-I Hsu
Division of Gastroenterology & Hepatology; Department of Internal Medicine, Kaohsiung Veterans General Hospital; Kaohsiung Taiwan
9 shared publications - Kwok-Hung Lai
Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
8 shared publications C K Lin
7 shared publications- Chiun-Ku Lin
Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, and National Yang-Ming University, Taipei, Taiwan, ROC
7 shared publications
Latest Publications
- Open Access
- 15 November 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1684-1711
Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.
- 15 November 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1684-1711
Open AccessNon-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.
- 14 June 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1943-1944
Response to Biswas et al
- 14 June 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1943-1944
Response to Biswas et al
- 25 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1821-1830
A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage
INTRODUCTION: This trial was to shorten the duration of both vasoconstrictors and prophylactic antibiotics to only 2 days in the therapy of acute gastroesophageal variceal hemorrhage. METHODS: After successful endoscopic hemostasis of gastroesophageal variceal hemorrhage, eligible patients were randomized to receive terlipressin infusion 1 mg per 6 hours and ceftriaxone 1 g daily for 5 days (group A) or a similar regimen for 2 days (group B). Primary end points were very early rebleeding at 5 days, and secondary end points included 48-hour hemostasis, 42-day rebleeding, and hospitalization days. RESULTS: Group A comprised 48 patients, and group B comprised 52 patients. Both groups were comparable in the severity of liver disease. Forty-eight-hour initial hemostasis was 95.8% in group A and 100% in group B (P = 0.13). Very early rebleeding between 3 and 5 days occurred in 1 patient (2.1%) in group A and 2 patients (3.8%) in group B (P = 0.60). The difference was 1.8% and the 95% confidence interval was −1.31% to 2.08%, which demonstrated noninferiority. Forty-two-day rebleeding occurred in 5 patients (10.4%) in group A and 4 patients (7.7%) in group B (P = 0.63). The median hospitalization days were 8.5 ± 3.8 days in group A vs 5.6 ± 2.6 days in group B (P < 0.001). DISCUSSION: After successful endoscopic hemostasis of acute variceal bleeding, combination of 2-day terlipressin infusion and ceftriaxone therapy was not inferior to the 5-day regimen in terms of very early rebleeding, with the advantage of shortening hospitalization stay.
- 25 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1821-1830
A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage
INTRODUCTION: This trial was to shorten the duration of both vasoconstrictors and prophylactic antibiotics to only 2 days in the therapy of acute gastroesophageal variceal hemorrhage. METHODS: After successful endoscopic hemostasis of gastroesophageal variceal hemorrhage, eligible patients were randomized to receive terlipressin infusion 1 mg per 6 hours and ceftriaxone 1 g daily for 5 days (group A) or a similar regimen for 2 days (group B). Primary end points were very early rebleeding at 5 days, and secondary end points included 48-hour hemostasis, 42-day rebleeding, and hospitalization days. RESULTS: Group A comprised 48 patients, and group B comprised 52 patients. Both groups were comparable in the severity of liver disease. Forty-eight-hour initial hemostasis was 95.8% in group A and 100% in group B (P = 0.13). Very early rebleeding between 3 and 5 days occurred in 1 patient (2.1%) in group A and 2 patients (3.8%) in group B (P = 0.60). The difference was 1.8% and the 95% confidence interval was −1.31% to 2.08%, which demonstrated noninferiority. Forty-two-day rebleeding occurred in 5 patients (10.4%) in group A and 4 patients (7.7%) in group B (P = 0.63). The median hospitalization days were 8.5 ± 3.8 days in group A vs 5.6 ± 2.6 days in group B (P < 0.001). DISCUSSION: After successful endoscopic hemostasis of acute variceal bleeding, combination of 2-day terlipressin infusion and ceftriaxone therapy was not inferior to the 5-day regimen in terms of very early rebleeding, with the advantage of shortening hospitalization stay.
- 18 December 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 306-321
Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing‐risk meta‐analysis of individual participant data
Background & Aims: Non‐selective β‐blockers (NSBBs) and endoscopic variceal‐ligation (EVL) have similar efficacy preventing first variceal bleeding. Compensated and decompensated cirrhosis are markedly different stages, which may impact treatment outcomes. We aimed to assess the efficacy of NSBBs vs EVL on survival in patients with high‐risk varices without previous bleeding, stratifying risk according to compensated/decompensated stage of cirrhosis.Methods: By systematic review, we identified RCTs comparing NSBBs vs EVL, in monotherapy or combined, for primary bleeding prevention. We performed a competing‐risk, time‐to‐event meta‐analysis, using individual patient data (IPD) obtained from principal investigators of RCTs. Analyses were stratified according to previous decompensation of cirrhosis.Results: Of 25 RCTs eligible, 14 failed to provide IPD and 11 were included, comprising 1400 patients (656 compensated, 744 decompensated), treated with NSBBs (N = 625), EVL (N = 546) or NSBB+EVL (N = 229). Baseline characteristics were similar between groups. Overall, mortality risk was similar with EVL vs. NSBBs (subdistribution hazard‐ratio (sHR) = 1.05, 95% CI = 0.75–1.49) and with EVL + NSBBs vs either monotherapy, with low heterogeneity (I2 = 28.7%). In compensated patients, mortality risk was higher with EVL vs NSBBs (sHR = 1.76, 95% CI = 1.11–2.77) and not significantly lower with NSBBs+EVL vs NSBBs, without heterogeneity (I2 = 0%). In decompensated patients, mortality risk was similar with EVL vs. NSBBs and with NSBBs+EVL vs. either monotherapy.Conclusions: In patients with compensated cirrhosis and high‐risk varices on primary prophylaxis, NSBBs significantly improved survival vs EVL, with no additional benefit noted adding EVL to NSBBs. In decompensated patients, survival was similar with both therapies. The study suggests that NSBBs are preferable when advising preventive therapy in compensated patients.
- 18 December 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 306-321
Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing‐risk meta‐analysis of individual participant data
Background & Aims: Non‐selective β‐blockers (NSBBs) and endoscopic variceal‐ligation (EVL) have similar efficacy preventing first variceal bleeding. Compensated and decompensated cirrhosis are markedly different stages, which may impact treatment outcomes. We aimed to assess the efficacy of NSBBs vs EVL on survival in patients with high‐risk varices without previous bleeding, stratifying risk according to compensated/decompensated stage of cirrhosis.Methods: By systematic review, we identified RCTs comparing NSBBs vs EVL, in monotherapy or combined, for primary bleeding prevention. We performed a competing‐risk, time‐to‐event meta‐analysis, using individual patient data (IPD) obtained from principal investigators of RCTs. Analyses were stratified according to previous decompensation of cirrhosis.Results: Of 25 RCTs eligible, 14 failed to provide IPD and 11 were included, comprising 1400 patients (656 compensated, 744 decompensated), treated with NSBBs (N = 625), EVL (N = 546) or NSBB+EVL (N = 229). Baseline characteristics were similar between groups. Overall, mortality risk was similar with EVL vs. NSBBs (subdistribution hazard‐ratio (sHR) = 1.05, 95% CI = 0.75–1.49) and with EVL + NSBBs vs either monotherapy, with low heterogeneity (I2 = 28.7%). In compensated patients, mortality risk was higher with EVL vs NSBBs (sHR = 1.76, 95% CI = 1.11–2.77) and not significantly lower with NSBBs+EVL vs NSBBs, without heterogeneity (I2 = 0%). In decompensated patients, mortality risk was similar with EVL vs. NSBBs and with NSBBs+EVL vs. either monotherapy.Conclusions: In patients with compensated cirrhosis and high‐risk varices on primary prophylaxis, NSBBs significantly improved survival vs EVL, with no additional benefit noted adding EVL to NSBBs. In decompensated patients, survival was similar with both therapies. The study suggests that NSBBs are preferable when advising preventive therapy in compensated patients.
- 3 February 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , E80
Letter to the Editor: Is embolization of large spontaneous shunt effective in the prevention of HE after TIPS?
- 3 February 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , E80
Letter to the Editor: Is embolization of large spontaneous shunt effective in the prevention of HE after TIPS?
- 3 September 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (2) , E32
Letter to the editor: Could COVID‐19 vaccination reduce postinfection mortality in most patients with cirrhosis?
- 3 September 2022
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (2) , E32
Letter to the editor: Could COVID‐19 vaccination reduce postinfection mortality in most patients with cirrhosis?
- Open Access
- 14 July 2021
- Published by SAGE Publications in Science Progress
- Vol. 104 (3)
Short-course vasoconstrictors are adequate for esophageal variceal bleeding after endoscopic variceal ligation: A systematic review and meta-analysis
Endoscopic variceal ligation (EVL) with vasoconstrictors has been recommended for acute esophageal variceal bleeding. However, the optimal duration of vasoconstrictors after EVL is controversial. This systematic review and meta-analysis was conducted to explore the efficacy of short-course vasoconstrictors (≤3 days) versus standard combination (3–5 days). A comprehensive literature review was conducted using the PubMed, Embase, and Cochrane library databases with subsequent meta-analysis. The primary outcomes were 5-day rebleeding, mortality, and treatment failure rates. A risk ratio (RR) with 95% confidence interval is used for outcome comparison. Nine randomized studies with 838 patients were included. The initial hemostasis (96.8% vs 97.4%, p = 0.919), 5-day rebleeding (11.2% vs 8.3%, RR = 1.05, 95% CI = 0.62–1.76), mortality (0 vs 1.3%, RR = 0.48, 95% CI = 0.10–2.39), and treatment failure (7.4% vs 5.9%, RR = 1.10, 95% CI = 0.48–2.49) were similar in both groups. Subgroup analysis suggested EVL alone had no significant difference of 5-day re-bleeding (15.9% vs 7.1%, RR = 2.25, 95% CI = 0.87–5.77), mortality (0 vs 0.7%, RR = 0.71, 95% CI = 0.08–6.03), treatment failure (9.6% vs 6.7%, RR = 1.43, 95% CI = 0.54–3.75) compared to standard combination. Clinical heterogeneity was found for the rebleeding rate for the subgroup during sensitivity analysis. EVL with short-course vasoconstrictors is highly efficacious for esophageal variceal bleeding. Further studies are required to determine the genuine need of subsequent vasoconstrictor after successful EVL.
- 14 July 2021
- Published by SAGE Publications in Science Progress
- Vol. 104 (3)
Open AccessShort-course vasoconstrictors are adequate for esophageal variceal bleeding after endoscopic variceal ligation: A systematic review and meta-analysis
Endoscopic variceal ligation (EVL) with vasoconstrictors has been recommended for acute esophageal variceal bleeding. However, the optimal duration of vasoconstrictors after EVL is controversial. This systematic review and meta-analysis was conducted to explore the efficacy of short-course vasoconstrictors (≤3 days) versus standard combination (3–5 days). A comprehensive literature review was conducted using the PubMed, Embase, and Cochrane library databases with subsequent meta-analysis. The primary outcomes were 5-day rebleeding, mortality, and treatment failure rates. A risk ratio (RR) with 95% confidence interval is used for outcome comparison. Nine randomized studies with 838 patients were included. The initial hemostasis (96.8% vs 97.4%, p = 0.919), 5-day rebleeding (11.2% vs 8.3%, RR = 1.05, 95% CI = 0.62–1.76), mortality (0 vs 1.3%, RR = 0.48, 95% CI = 0.10–2.39), and treatment failure (7.4% vs 5.9%, RR = 1.10, 95% CI = 0.48–2.49) were similar in both groups. Subgroup analysis suggested EVL alone had no significant difference of 5-day re-bleeding (15.9% vs 7.1%, RR = 2.25, 95% CI = 0.87–5.77), mortality (0 vs 0.7%, RR = 0.71, 95% CI = 0.08–6.03), treatment failure (9.6% vs 6.7%, RR = 1.43, 95% CI = 0.54–3.75) compared to standard combination. Clinical heterogeneity was found for the rebleeding rate for the subgroup during sensitivity analysis. EVL with short-course vasoconstrictors is highly efficacious for esophageal variceal bleeding. Further studies are required to determine the genuine need of subsequent vasoconstrictor after successful EVL.
- 21 June 2021
- Published by Wiley in Liver International
- Vol. 41 (11) , 2671-2680
Drug‐induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan
Background & Aims: Severe cutaneous adverse drug reactions (SCARs) including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are high‐mortality adverse drug reactions. The risk factors and prognosis of drug‐induced liver injury (DILI) concomitant with SCAR warrant clarification. We aimed to evaluate the characteristics and outcomes of DILI with SCAR.Methods: We analysed the database of a 10‐year multi‐centre prospective study in Taiwan from 2011 to 2020.Results: A total of 1415 patients with DILI were enrolled, including 81 cases combined with SJS/TEN, 74 with DRESS, 3 with AGEP and 1257 with pure DILI. Approximated 11.2% of patients had SCAR, of which allopurinol was the leading incriminated drug, followed by sulphonamides and carbamazepine. The SJS/TEN group had the highest mortality (34.6%). Jaundice, acute kidney injury and SJS/TEN were independent risk factors of mortality (odds ratio: 29.54, 4.43 and 4.86, respectively, P < .003). Chronic kidney disease with high‐dose allopurinol also contributed to high mortality (78.9%) in cases of allopurinol‐induced DILI with SCAR. The HLA‐B*5801 was associated with a high risk and mortality of allopurinol‐induced DILI with SCAR. Likewise, the HLA‐B*1502 was closely related to carbamazepine‐induced DILI with SCAR.Conclusions: DILI patients combined with SCAR are common and have a high mortality in Taiwan. Allopurinol is the leading incriminated drug. Jaundice, acute kidney injury and SJS/TEN are risk factors of mortality. HLA‐B*5801, chronic kidney disease and high drug dosage also contribute to high mortality in allopurinol‐induced DILI with SCAR.
- 21 June 2021
- Published by Wiley in Liver International
- Vol. 41 (11) , 2671-2680
Drug‐induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan
Background & Aims: Severe cutaneous adverse drug reactions (SCARs) including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are high‐mortality adverse drug reactions. The risk factors and prognosis of drug‐induced liver injury (DILI) concomitant with SCAR warrant clarification. We aimed to evaluate the characteristics and outcomes of DILI with SCAR.Methods: We analysed the database of a 10‐year multi‐centre prospective study in Taiwan from 2011 to 2020.Results: A total of 1415 patients with DILI were enrolled, including 81 cases combined with SJS/TEN, 74 with DRESS, 3 with AGEP and 1257 with pure DILI. Approximated 11.2% of patients had SCAR, of which allopurinol was the leading incriminated drug, followed by sulphonamides and carbamazepine. The SJS/TEN group had the highest mortality (34.6%). Jaundice, acute kidney injury and SJS/TEN were independent risk factors of mortality (odds ratio: 29.54, 4.43 and 4.86, respectively, P < .003). Chronic kidney disease with high‐dose allopurinol also contributed to high mortality (78.9%) in cases of allopurinol‐induced DILI with SCAR. The HLA‐B*5801 was associated with a high risk and mortality of allopurinol‐induced DILI with SCAR. Likewise, the HLA‐B*1502 was closely related to carbamazepine‐induced DILI with SCAR.Conclusions: DILI patients combined with SCAR are common and have a high mortality in Taiwan. Allopurinol is the leading incriminated drug. Jaundice, acute kidney injury and SJS/TEN are risk factors of mortality. HLA‐B*5801, chronic kidney disease and high drug dosage also contribute to high mortality in allopurinol‐induced DILI with SCAR.
- 27 January 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 53 (02) , 211
Reply to Singh et al.
We would like to thank Dr. Singh and colleagues for their interest in our article [1]. Regarding the endoscopic therapy of GOV1, our previous prospective and retrospective studies both showed that glue injection could be more effective than banding ligation for acute hemostasis and was associated with fewer episodes of ulcer bleeding [2] [3]. The sizes of gastric varices were shown in Table 1. The majority of both groups had moderate or severe gastric varices. Possibly because of the small sample size, no correlation existed between variceal size and acute hemostasis. It is true that experience is required in performing the glue injections. In this trial, all three endoscopists had good levels of experience in the technique of glue injection. Publication Date: 27 January 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 January 2021
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 53 (02) , 211
Reply to Singh et al.
We would like to thank Dr. Singh and colleagues for their interest in our article [1]. Regarding the endoscopic therapy of GOV1, our previous prospective and retrospective studies both showed that glue injection could be more effective than banding ligation for acute hemostasis and was associated with fewer episodes of ulcer bleeding [2] [3]. The sizes of gastric varices were shown in Table 1. The majority of both groups had moderate or severe gastric varices. Possibly because of the small sample size, no correlation existed between variceal size and acute hemostasis. It is true that experience is required in performing the glue injections. In this trial, all three endoscopists had good levels of experience in the technique of glue injection. Publication Date: 27 January 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 July 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 52 (08) , 709
Should we pursue high obliteration rate or high hemostatic rate in the therapy of gastric varices?
I read with interest the article regarding the therapy of gastric varices by Robles-Medranda et al. [1]. The investigators demonstrated that endoscopic ultrasonography (EUS)-guided coil embolization with cyanoacrylate injection achieved a lower rate of rebleeding and reintervention than coil treatment alone. The obliteration rates were up to 100 % and 90 %, respectively. These figures are definitely superior to those for standard endoscopic cyanoacrylate injection [2] [3] [4]. The acute hemostatic rates were not disclosed in the current trial. Five patients (17 %) in each group died of uncontrolled hemorrhage and the mortality rates were around 30 % at follow-up of only 12 months. These data seem to be no better than those for standard endoscopic cyanoacrylate injection [2] [3] [4]. EUS-guided coil embolization with cyanoacrylate injection appears rather appealing to endoscopists. However, this time-consuming, difficult technique may be more beneficial for a few selected individuals with severe gastric varices. Standard endoscopic cyanoacrylate injection has the advantage of being easy to perform and could be more accessible for endoscopists worldwide. Publication Date: 28 July 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York
- 28 July 2020
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 52 (08) , 709
Should we pursue high obliteration rate or high hemostatic rate in the therapy of gastric varices?
I read with interest the article regarding the therapy of gastric varices by Robles-Medranda et al. [1]. The investigators demonstrated that endoscopic ultrasonography (EUS)-guided coil embolization with cyanoacrylate injection achieved a lower rate of rebleeding and reintervention than coil treatment alone. The obliteration rates were up to 100 % and 90 %, respectively. These figures are definitely superior to those for standard endoscopic cyanoacrylate injection [2] [3] [4]. The acute hemostatic rates were not disclosed in the current trial. Five patients (17 %) in each group died of uncontrolled hemorrhage and the mortality rates were around 30 % at follow-up of only 12 months. These data seem to be no better than those for standard endoscopic cyanoacrylate injection [2] [3] [4]. EUS-guided coil embolization with cyanoacrylate injection appears rather appealing to endoscopists. However, this time-consuming, difficult technique may be more beneficial for a few selected individuals with severe gastric varices. Standard endoscopic cyanoacrylate injection has the advantage of being easy to perform and could be more accessible for endoscopists worldwide. Publication Date: 28 July 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York